The Second Generation Sulfonylureas: Glipizide and Glyburide
1985
Baker, Danial E. | Campbell, Keith (R. Keith)
Glyburide and glipizide are approved by the FDA for treatment of symptomatic and asymp tomatic NIDDM patients in whom hyperglycemia cannot be satisfactorily controlled by diet and exercise. Pharmacology studies suggest that glyburide and glipizide sensitize the beta cells of the pancreas to release insulin only in the presence of elevated serum glucose levels. Long-term efficacy appears to depend on extrapancreatic effects, suppressing hepatic glucose production, and improved postreceptor insulin activity.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by National Agricultural Library